Format

Send to

Choose Destination
Cancer Biol Ther. 2016;17(2):129-38. doi: 10.1080/15384047.2015.1108486. Epub 2015 Dec 9.

Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.

Author information

1
a Department of Surgical Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
2
b The Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
3
c Department of Pathology and Genomic Medicine , Houston Methodist Hospital , Houston , TX , USA.
4
d Department of Pathology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
5
e Department of Biochemistry and Molecular Biology , The University of Texas-Medical School , Houston , TX , USA.
6
f Department of Neuro-Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
7
g Department of Neurosurgery , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
8
h Department of Surgery , The Ohio State University, Wexner Medical Center , Columbus , OH , USA.
9
i Department of Surgery , Sheba Medical Center, Tel Aviv University , Tel Aviv , Israel.

Abstract

Poly (ADP) ribose polymerase (PARP) inhibitors, first evaluated nearly a decade ago, are primarily used in malignancies with known defects in DNA repair genes, such as alterations in breast cancer, early onset 1/2 (BRCA1/2). While no specific mutations in BRCA1/2 have been reported in malignant peripheral nerve sheath tumors (MPNSTs), MPNST cells could be effectively targeted with a PARP inhibitor to drive cells to synthetic lethality due to their complex karyotype and high level of inherent genomic instability. In this study, we assessed the expression levels of PARP1 and PARP2 in MPNST patient tumor samples and correlated these findings with overall survival. We also determined the level of PARP activity in MPNST cell lines. In addition, we evaluated the efficacy of the PARP inhibitor AZD2281 (Olaparib) in MPNST cell lines. We observed decreased MPNST cell proliferation and enhanced apoptosis in vitro at doses similar to, or less than, the doses used in cell lines with established defective DNA repair genes. Furthermore, AZD2281 significantly reduced local growth of MPNST xenografts, decreased the development of macroscopic lung metastases, and increased survival of mice with metastatic disease. Our results suggest that AZD2281 could be an effective therapeutic option in MPNST and should be further investigated for its potential clinical use in this malignancy.

KEYWORDS:

AZD2281 (Olaparib); PARP inhibitor; malignant peripheral nerve sheath tumor (MPNST); poly (ADP) ribose polymerase (PARP); soft tissue sarcoma

PMID:
26650448
PMCID:
PMC4847988
DOI:
10.1080/15384047.2015.1108486
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center